Glenmark Pharmaceuticals Limited

NSE: GLENMARK

Healthcare Healthcare

₹2,176.5

+0.48%EOD · 8 Jun

Glenmark Pharmaceuticals Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap

₹61,421 Cr

52W Range

₹2440 / ₹1589

Volume

491K

35.1% delivery

1Y Return

+30.3%

P/E Ratio

44.8

P/B Ratio

6.4

ROE

14.1%

Debt / Equity

5.65

Peers in Healthcare

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
Glenmark Pharmaceuticals Limited(this stock)	₹2,176.5	₹61,421 Cr	44.8	6.4	14.1%	0.23%
Divi's Laboratories LimitedDIVISLAB	₹6,521	₹1.73 L Cr	68.5	10.5	16.2%	0.45%
Torrent Pharmaceuticals LimitedTORNTPHARM	₹4,410.4	₹1.49 L Cr	69.0	17.7	17.0%	0.86%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP	₹8,358.5	₹1.20 L Cr	61.4	12.6	21.5%	0.24%
Zydus Lifesciences LimitedZYDUSLIFE	₹1,087.6	₹1.09 L Cr	21.7	4.3	18.3%	0.09%
Max Healthcare Institute LimitedMAXHEALTH	₹1,007.45	₹98,049 Cr	66.2	8.8	14.3%	0.15%
Mankind Pharma LimitedMANKIND	₹2,357.4	₹97,339 Cr	50.5	6.3	12.4%	0.09%
Aurobindo Pharma LimitedAUROPHARMA	₹1,451.8	₹83,533 Cr	24.2	2.2	9.9%	0.27%
Laurus Labs LimitedLAURUSLABS	₹1,404.7	₹75,889 Cr	92.6	14.7	17.7%	0.17%

Technical Indicators

Full analysis · objective math, not advice

Returns

+0.5%

-0.4%

-7.0%

+3.2%

+13.2%

+30.3%

Weinstein Stage

Stage 2 — Advancing (uptrend)

RSI (14)

39 Neutral

Trend Template

6/7strong

Moving Averages (price vs MA)

20-DMA

₹2281

below

50-DMA

₹2245

below

150-DMA

₹2084

above

200-DMA

₹2052

above

From 52W High

-10.8%

From 52W Low

+33.9%

Support (20D)

₹2132

Resistance (20D)

₹2427

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Quality Signals

Multi-year consistency · Source: Screener annual data

ROE Consistency

0/0 years ≥15%

Revenue Growth

+4.7% CAGR

Up 8 of last 11 years

Earnings Quality

Accrual-heavy (watch)

OCF / Net Profit = 0.37x · 11/12 yrs +ve cash flow

Quality signals derived from multi-year annual financials. ROE consistency = years with ≥15% return on equity. Cash-backed = operating cash flow vs reported net profit (≥1x means earnings are converted to real cash, not just accruals). Educational reference only — not investment advice.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.